Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Eloralintide

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Eli Lilly · Phase 2 · Recruiting · Enrollment 400

NCT07589608

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Macupatide Dose 1n/rn/rn/rn/r
Eloralintide Dose 1n/rn/rn/rn/r
Macupatide Dose 1 + Eloralintide Dose 1n/rn/rn/rn/r
Eloralintide Dose 2n/rn/rn/rn/r
Macupatide Dose 1 + Eloralintide Dose 2n/rn/rn/rn/r
Eloralintide Dose 3n/rn/rn/rn/r
Macupatide Dose 2 + Eloralintide Dose 3n/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Macupatide Dose 1: endpoint not reported
  • Eloralintide Dose 1: endpoint not reported
  • Macupatide Dose 1 + Eloralintide Dose 1: endpoint not reported
  • Eloralintide Dose 2: endpoint not reported
  • Macupatide Dose 1 + Eloralintide Dose 2: endpoint not reported
  • Eloralintide Dose 3: endpoint not reported
  • Macupatide Dose 2 + Eloralintide Dose 3: endpoint not reported
  • Placebo: endpoint not reported